Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that Dr. Heman Chao, Helix’s Chief Executive Officer, will be presenting at NobleCon - Noble Capital Markets’ Sixteenth Annual Investor Conference at the Hard Rock Hotel & Casino, Hollywood, Florida
RICHMOND HILL, Ontario, Feb. 14, 2020 (GLOBE NEWSWIRE) -- Helix Biopharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that Dr. Heman Chao, Helix’s Chief Executive Officer, will be presenting at NobleCon - Noble Capital Markets’ Sixteenth Annual Investor Conference at the Hard Rock Hotel & Casino, Hollywood, Florida - on Monday, February 17th at 3:00PM Eastern Standard Time (https://www.nobleconference.com/sixteen#home).
In addition to the company’s presentation on Monday, February 17th Dr. Chao has been invited to be a panelist on “Cancer Treatment: Tackling the Disease Through Innovative Strategies”. The panel discussion is being held on February 17th between 5:30pm and 6:30pm in Terrace Ballroom D. The panel will discuss current revolutionary new strategies to defeat cancer, including innate immunity, modulation of tumor micro-environment, treatment of solid tumors with CAR-T, cancer vaccines and cell cycle inhibitors.
Furthermore, Helix has been selected to present to Noble Capital Markets Life Sciences Scientific and Advisory Board (“LSAB”), in an invitation only event. Noble Capital Markets’ LSAB is composed of world-class healthcare professionals with extensive experience in the medical and pharmaceutical industries.
“We are very pleased to be presenting at this conference in addition to having been invited to partake in a panel discussion and to present Helix’s technology to Noble Capital Markets Life Sciences Scientific and Advisory Board”, said Dr. Chao. “We look forward to introducing Helix to a wider investment community”.
A high-definition video of Helix’s presentation will be available the following day on the Company’s website at www.helixbiopharma.com and will also be available on Noble Capital Markets’ conference website at www.nobleconference.com as part of the conference’s complete catalogue of presentations and on Noble Capital Markets’ investor portal website, Channelchek, at www.channelchek.com.
About NobleCon
Noble Capital Markets’ 16th Annual Emerging Growth Investor Conference - a multi-sector blend of emerging growth companies with total representation limited to 125 public companies. Four presentation tracks run simultaneously each half hour over two days. One-on-one meetings between qualified investors and corporate executives are arranged and scheduled on behalf of participants. Topical panel presentations open to all attendees. Comprehensive evening networking events. Registration for investors is open to institutions, registered investment advisors, family offices, self-directed high-net-worth individuals and independent brokers.
About Helix BioPharma Corp.
Helix BioPharma Corp. is an immuno-oncology company specializing in the field of cancer therapy. The company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix’s product development initiatives include its novel L-DOS47 new drug candidate and Chimeric Antigen Receptor (“CAR”) based cell therapies. Helix is currently listed on the TSX under the symbol “HBP”.
About DOS47
DOS47 is based upon a naturally occurring enzyme isolated from the jack-bean plant called urease that breaks down a natural substance found in the body, urea, into metabolites that include ammonia and hydroxyl ions. By doing so at the site of cancerous tissues in the body, the Company believes DOS47 can modify the micro environmental conditions of cancerous cells in a manner that leads to apoptosis. DOS47 stimulates an increase in the pH of the microenvironment surrounding the cancerous cells, effectively reversing the acidic extra-cellular conditions that are believed to act to defend tumour cells.
About L-DOS47
L-DOS47 is Helix’s first immunoconjugate based drug candidate in development based on the Company’s novel DOS47 platform technology, which is designed to use an innovative approach to modify the microenvironmental conditions of cancer cells in a manner that leads to their destruction.
Investor Relations
Helix BioPharma Corp.
9120 Leslie Street, Suite 205
Richmond Hill, Ontario, L4B 3J9
Tel: 905-841-2300
Email: ir@helixbiopharma.com
Cautionary Statements
This news release may contain forward-looking statements with respect to Helix, its operations, strategy, financial performance and condition, including its activities relating to its drug development program, any anticipated timelines for the commencement or completion of certain activities such as raising sufficient capital, merger and acquisition activity, listing on a U.S. exchange and other information in future periods. These statements generally can be identified by use of forward-looking words such as “aims”, “transform”, “should”, “may”, “will”, “expect”, “estimate”, “anticipate”, “intends”, “believe” or “continue” or the negative thereof or similar variations. The actual results and performance of discussed herein could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations, including: (i) Helix’s ability to operate as a going concern being dependent mainly on securing sufficient additional financing in order to fund its ongoing research and development and other operating activities; (ii) the generally inherent uncertainty involved in scientific research and drug development and those specific to Helix’s pre-clinical and clinical development programs (DOS47, L-DOS47, V-DOS47 and CAR-T); (iii) that any transactions contemplated herein are completed; and (iv) those risks and uncertainties affecting Helix as more fully described in Helix’s most recent Annual Information Form, which is available at www.sedar.com (together, the “Helix Risk Factors”). Certain material factors and assumptions are applied in making the forward-looking statements, including, without limitation, that sufficient financing will be obtained in a timely manner to allow Helix to continue operations and implement its clinical trials in the manner and on the timelines anticipated and that the Helix Risk Factors will not cause Helix’s actual results or events to differ materially from the forward-looking statements. These cautionary statements qualify all such forward-looking statements.
Forward-looking statements and information are based on the beliefs, assumptions, opinions, plans and expectations of Helix’s management on the date of this news release, and the Company does not assume any obligation to update any forward-looking statement or information should those beliefs, assumptions, opinions, plans or expectations, or other circumstances change, except as required by law.
